195 related articles for article (PubMed ID: 29966441)
21. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
[TBL] [Abstract][Full Text] [Related]
23. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer.
Yang X; Zheng F; Xing H; Gao Q; Wei W; Lu Y; Wang S; Zhou J; Hu W; Ma D
J Cancer Res Clin Oncol; 2004 Jul; 130(7):423-8. PubMed ID: 15156398
[TBL] [Abstract][Full Text] [Related]
24. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
25. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
26. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
27. Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas.
Wu J; Li QQ; Zhou H; Lu Y; Li JM; Ma Y; Wang L; Fu T; Gong X; Weintraub M; Wu S; Ding H
Med Oncol; 2014 Jul; 31(7):14. PubMed ID: 24880464
[TBL] [Abstract][Full Text] [Related]
28. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
29. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract][Full Text] [Related]
30. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer.
Han X; Liu D; Zhou Y; Wang L; Hou H; Chen H; Zhang L; Chen W; Li X; Zhao L
Cell Biol Int; 2021 Jan; 45(1):227-237. PubMed ID: 33090550
[TBL] [Abstract][Full Text] [Related]
31. Triptolide inhibits benign prostatic epithelium viability and migration and induces apoptosis via upregulation of microRNA-218.
Yao C; Li H; Zhang W
Int J Immunopathol Pharmacol; 2018; 32():2058738418812349. PubMed ID: 30453799
[TBL] [Abstract][Full Text] [Related]
32. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
Li SG; Shi QW; Yuan LY; Qin LP; Wang Y; Miao YQ; Chen Z; Ling CQ; Qin WX
J Exp Clin Cancer Res; 2018 Mar; 37(1):51. PubMed ID: 29523159
[TBL] [Abstract][Full Text] [Related]
33. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.
Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X
Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354
[TBL] [Abstract][Full Text] [Related]
34. [Triptolide reverses apatinib resistance in gastric cancer cell line MKN45 via inhibition of heat shock protein 70].
Teng F; Xu ZY; Lyu H; Wang YP; Wang LJ; Huang T; Sun JC; Zhu HT; Ni YX; Cheng XD
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):92-98. PubMed ID: 29502367
[No Abstract] [Full Text] [Related]
35. Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin.
Zhao H; Yang Z; Wang X; Zhang X; Wang M; Wang Y; Mei Q; Wang Z
Exp Mol Med; 2012 Nov; 44(11):633-41. PubMed ID: 22902510
[TBL] [Abstract][Full Text] [Related]
36. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
37. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
38. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
[TBL] [Abstract][Full Text] [Related]
39. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
40. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.
Duiker EW; Meijer A; van der Bilt AR; Meersma GJ; Kooi N; van der Zee AG; de Vries EG; de Jong S
Br J Cancer; 2011 Apr; 104(8):1278-87. PubMed ID: 21487429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]